Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Goetz on the MONARCH Trials for Breast Cancer

January 30th 2018

Matthew P. Goetz, MD, professor of oncology and pharmacology, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the MONARCH trials for patients with breast cancer.

Combos May Extend Reach of CDK4/6 Inhibitors in Breast Cancer

January 29th 2018

Oncology drug developers have been able to leverage knowledge about a cause of proliferation— dysregulated activity of the cyclin-dependent kinases (CDKs)—to create a new class of therapy that has rapidly been integrated into the breast cancer treatment paradigm.

Dr. Ellis on Immunotherapy in HER2+ Breast Cancer

January 23rd 2018

Matthew J. Ellis, MD, PhD, professor of oncology and medicine at Baylor College of Medicine, discusses developments with immunotherapy for patients with HER2-positive breast cancer.

Study Finds No Cardiac Toxicity Increase With Trastuzumab in HER2+ Breast Cancer Patients

January 17th 2018

Trastuzumab did not reduce cardiac function in women with node-positive, HER2+, early-stage breast cancer.

Progress for TNBC Seen Across Treatment Modalities

January 15th 2018

Although chemotherapy remains the mainstay of treatment for patients with triple-negative breast cancer, promising developments are unfolding on several fronts, including new ways of using existing therapies and the exploration of immunotherapy, novel antibodies, and agents targeting the PI3K/mTOR/AKT pathway.

Dr. Brufsky on the FDA Approval of Olaparib in BRCA+ Breast Cancer

January 12th 2018

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses the FDA approval of olaparib (Lynparza) for the treatment of patients with germline BRCA-positive, HER2-negative metastatic breast cancer who have previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic settings.

FDA Approves Olaparib for BRCA+ Breast Cancer

January 12th 2018

The FDA approved the PARP inhibitor olaparib (Lynparza) for the treatment of patients with germline BRCA-positive, HER2-negative metastatic breast cancer.

Dr. Domchek on Promising Biomarkers in Breast Cancer

January 9th 2018

Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses promising biomarkers in breast cancer.

Novel Treatments Emerging in HER2+ Breast Cancer Pipeline

January 8th 2018

Aleix Prat, MD, PhD, discusses the novel treatments being developed in the paradigm of HER2-positive breast cancer.

Dr. Yardley Discusses Enzalutamide in HR+ Breast Cancer

January 6th 2018

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the randomized placebo-controlled phase II trial evaluating exemestane with/without enzalutamide (Xtandi) in patients with hormone receptor (HR)-positive breast cancer

Analysis Confirms Safety of Olaparib in Breast Cancer

January 5th 2018

An analysis of the phase III OlympiAD study showed that treatment discontinuation due to toxicity was less frequent with olaparib (Lynparza) monotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation.

Dr. Tolaney on the Evolution of Adjuvant Treatment for HER2+ Breast Cancer

January 3rd 2018

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the evolution of adjuvant treatment for patients with HER2-positive breast cancer.

FDA Grants Ribociclib Breakthrough Designation for HR+/HER2- Premenopausal Breast Cancer

January 3rd 2018

The FDA has granted ribociclib a breakthrough therapy designation for use in combination with tamoxifen or an aromatase inhibitor as frontline treatment for pre- or perimenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.

Controversies and Clinical Trials for DCIS: Margins and Active Surveillance

January 1st 2018

The management of ductal carcinoma in situ is one of the most controversial areas in breast cancer management.

Dual HER2 Blockade Superior for PFS in HER2+/HR+ Metastatic Breast Cancer

December 29th 2017

The combination of lapatinib, trastuzumab, and an aromatase inhibitor (AI) reduced the risk for death or progression by 38% in women with HER2+/HR+ metastatic breast cancer compared with those treated with a targeted agent plus AI.

Long-Term Data Published for Neratinib in HER2+ Breast Cancer

December 29th 2017

Extended adjuvant therapy with neratinib significantly reduced the proportion of clinically relevant breast cancer relapses without increasing the risk of long-term toxicity.

Hamilton Highlights Treatment Landscape of HER2+ Breast Cancer

December 28th 2017

Erika P. Hamilton, MD, discusses recent FDA approvals in the treatment paradigm of HER2-positive breast cancer.

FDA Approves Stereotactic Radiotherapy System for Breast Cancer

December 22nd 2017

The FDA has approved a new breast-specific stereotactic body radiotherapy device known as GammaPod as a treatment for patients with breast cancer, based on findings from a 17-patient study.

NICE Recommends Approval for Ribociclib, Palbociclib for HR+/ HER2- Advanced Breast Cancer

December 21st 2017

The United Kingdom's National Institute for Health and Care Excellence has issued guidance supporting approval for ribociclib and palbociclib for patients with hormone receptor-positive/HER2-negative locally advanced or secondary breast cancer.

Dr. Hamilton on FDA Approval of Adjuvant Pertuzumab Regimen in HER2+ Early Breast Cancer

December 21st 2017

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of pertuzumab (Perjeta) for use in combination with trastuzumab (Herceptin) and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer.